Insider Selling: Twist Bioscience Co. (NASDAQ:TWST) Insider Sells 1,507 Shares of Stock

Twist Bioscience Co. (NASDAQ:TWST) insider Dennis Cho sold 1,507 shares of the stock in a transaction dated Monday, November 11th. The stock was sold at an average price of $48.00, for a total value of $72,336.00. Following the sale, the insider now owns 91,163 shares of the company’s stock, valued at $4,375,824. This represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

Dennis Cho also recently made the following trade(s):

• On Monday, November 4th, Dennis Cho sold 659 shares of Twist Bioscience stock. The stock was sold at an average price of $41.56, for a total value of $27,388.04.
• On Wednesday, October 2nd, Dennis Cho sold 3,104 shares of Twist Bioscience stock. The shares were sold at an average price of $43.21, for a total transaction of $134,123.84.
• On Friday, September 20th, Dennis Cho sold 234 shares of Twist Bioscience stock. The stock was sold at an average price of $46.94, for a total transaction of $10,983.96.

Twist Bioscience Trading Down 6.1 %

Shares of TWST traded down $2.77 during midday trading on Wednesday, hitting $42.49. The stock had a trading volume of 962,106 shares, compared to its average volume of 941,048. Twist Bioscience Co. has a 1 year low of $18.59 and a 1 year high of $60.90. The stock’s 50 day moving average is $43.86 and its 200 day moving average is $45.95.

Analyst Upgrades and Downgrades

TWST has been the subject of several research reports. Evercore ISI increased their price objective on shares of Twist Bioscience from $52.00 to $56.00 and gave the company an “outperform” rating in a report on Tuesday, October 1st. JPMorgan Chase & Co. raised their price target on Twist Bioscience from $28.00 to $35.00 and gave the company an “underweight” rating in a report on Monday, August 5th. Barclays reduced their price objective on Twist Bioscience from $60.00 to $55.00 and set an “overweight” rating on the stock in a research note on Monday, August 5th. Leerink Partners boosted their price target on shares of Twist Bioscience from $45.00 to $48.00 and gave the stock a “market perform” rating in a research report on Thursday, October 17th. Finally, Robert W. Baird increased their price objective on shares of Twist Bioscience from $40.00 to $46.00 and gave the company an “outperform” rating in a research report on Monday, August 5th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and seven have assigned a buy rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $51.22.

Institutional Trading of Twist Bioscience

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in TWST. American International Group Inc. lifted its position in shares of Twist Bioscience by 0.8% during the first quarter. American International Group Inc. now owns 28,506 shares of the company’s stock worth $978,000 after purchasing an additional 213 shares during the last quarter. Caprock Group LLC increased its stake in Twist Bioscience by 2.9% in the 2nd quarter. Caprock Group LLC now owns 7,851 shares of the company’s stock worth $387,000 after buying an additional 220 shares during the period. Signaturefd LLC boosted its position in Twist Bioscience by 63.0% in the 3rd quarter. Signaturefd LLC now owns 792 shares of the company’s stock valued at $36,000 after buying an additional 306 shares during the period. Arizona State Retirement System boosted its position in Twist Bioscience by 1.9% in the 2nd quarter. Arizona State Retirement System now owns 16,187 shares of the company’s stock valued at $798,000 after buying an additional 308 shares during the period. Finally, Massachusetts Financial Services Co. MA grew its stake in Twist Bioscience by 3.5% in the 2nd quarter. Massachusetts Financial Services Co. MA now owns 9,279 shares of the company’s stock worth $457,000 after acquiring an additional 312 shares in the last quarter.

Twist Bioscience Company Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.